{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:44:14Z","timestamp":1785300254069,"version":"3.55.0"},"reference-count":63,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cantonal Hospital St Gallen Research Committee","award":["21\/20"],"award-info":[{"award-number":["21\/20"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Targeting proteasome with proteasome inhibitors (PIs) is an approved treatment strategy in multiple myeloma that has also been explored pre-clinically and clinically in other hematological malignancies. The approved PIs target both the constitutive and the immunoproteasome, the latter being present predominantly in cells of lymphoid origin. Therapeutic targeting of the immunoproteasome in cells with sole immunoproteasome activity may be selectively cytotoxic in malignant cells, while sparing the non-lymphoid tissues from the on-target PIs toxicity. Using activity-based probes to assess the proteasome activity profile and correlating it with the cytotoxicity assays, we identified B-cell chronic lymphocytic leukemia (B-CLL) to express predominantly immunoproteasome activity, which is associated with high sensitivity to approved proteasome inhibitors and, more importantly, to the immunoproteasome selective inhibitors LU005i and LU035i, targeting all immunoproteasome active subunits or only the immunoproteasome \u03b25i, respectively. At the same time, LU102, a proteasome \u03b22 inhibitor, sensitized B-CLL or immunoproteasome inhibitor-inherently resistant primary cells of acute myeloid leukemia, B-cell acute lymphoblastic leukemia, multiple myeloma and plasma cell leukemia to low doses of LU035i. The immunoproteasome thus represents a novel therapeutic target, which warrants further testing with clinical stage immunoproteasome inhibitors in monotherapy or in combinations.<\/jats:p>","DOI":"10.3390\/cells11050838","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T08:17:03Z","timestamp":1646122623000},"page":"838","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors"],"prefix":"10.3390","volume":"11","author":[{"given":"Andrej","family":"Besse","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Oncology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, 9000 St. Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Kraus","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Oncology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, 9000 St. Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Mendez-Lopez","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Oncology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, 9000 St. Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9631-9152","authenticated-orcid":false,"given":"Elmer","family":"Maurits","sequence":"additional","affiliation":[{"name":"Gorlaeus Laboratories, Leiden Institute of Chemistry, 2333 CC Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman S.","family":"Overkleeft","sequence":"additional","affiliation":[{"name":"Gorlaeus Laboratories, Leiden Institute of Chemistry, 2333 CC Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Driessen","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Oncology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, 9000 St. Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4739-7618","authenticated-orcid":false,"given":"Lenka","family":"Besse","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Oncology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, 9000 St. Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","article-title":"New directions for emerging therapies in acute myeloid leukemia: The next chapter","volume":"10","author":"Daver","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Furstenau, M., and Eichhorst, B. (2021). Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance. Cancers, 13.","DOI":"10.3390\/cancers13061336"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11899-020-00591-4","article-title":"Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia","volume":"15","author":"Gavralidis","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Gurnari, C., Pagliuca, S., and Visconte, V. (2020). Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228505"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/EDBK_280175","article-title":"Recent Advances in Managing Acute Lymphoblastic Leukemia","volume":"40","author":"DeAngelo","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/bloodadvances.2020003423","article-title":"Overcoming resistance to targeted therapies in chronic lymphocytic leukemia","volume":"5","author":"Skanland","year":"2021","journal-title":"Blood Adv."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Davis, L.N., and Sherbenou, D.W. (2021). Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13071686"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"10976","DOI":"10.1073\/pnas.96.20.10976","article-title":"The catalytic sites of 20S proteasomes and their role in subunit maturation: A mutational and crystallographic study","volume":"96","author":"Groll","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"25200","DOI":"10.1074\/jbc.272.40.25200","article-title":"The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing","volume":"272","author":"Heinemeyer","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1097-2765(00)80341-X","article-title":"Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown","volume":"4","author":"Kisselev","year":"1999","journal-title":"Mol. Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","article-title":"Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors","volume":"26","author":"Besse","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3324\/haematol.2014.109421","article-title":"The novel beta2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells","volume":"100","author":"Kraus","year":"2015","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.chembiol.2016.12.016","article-title":"Inhibition of the Proteasome beta2 Site Sensitizes Triple-Negative Breast Cancer Cells to beta5 Inhibitors and Suppresses Nrf1 Activation","volume":"24","author":"Weyburne","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-021-00414-6","article-title":"A clinical perspective on plasma cell leukemia; current status and future directions","volume":"11","author":"Tuazon","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_16","first-page":"4570","article-title":"Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia","volume":"9","author":"Pahler","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-15-2522","article-title":"Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses","volume":"22","author":"Lamothe","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/sj.leu.2402201","article-title":"Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex","volume":"15","author":"Almond","year":"2001","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1158\/1078-0432.CCR-12-2754","article-title":"The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-kappaB response in chronic lymphocytic leukemia cells","volume":"19","author":"Gupta","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood-2012-02-407999","article-title":"Cytotoxic effects of bortezomib in myelodysplastic syndrome\/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1","volume":"120","author":"Fang","year":"2012","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-2141.2007.06504.x","article-title":"The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells","volume":"136","author":"Stapnes","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Takahashi, K., Inukai, T., Imamura, T., Yano, M., Tomoyasu, C., Lucas, D.M., Nemoto, A., Sato, H., Huang, M., and Abe, M. (2017). Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0188680"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/cncr.22097","article-title":"Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia","volume":"107","author":"Faderl","year":"2006","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.3109\/10428194.2015.1014368","article-title":"Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"56","author":"Awan","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3109\/10428194.2015.1076930","article-title":"A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia","volume":"57","author":"Wartman","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_26","first-page":"705714","article-title":"Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed\/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy","volume":"2013","author":"Sarlo","year":"2013","journal-title":"Leuk. Res. Treatment."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41590-018-0186-z","article-title":"The immunoproteasome and thymoproteasome: Functions, evolution and human disease","volume":"19","author":"Murata","year":"2018","journal-title":"Nat. Immunol"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1756-8722-7-7","article-title":"Interferon-gamma-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines","volume":"7","author":"Niewerth","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-015-0529-1","article-title":"Proteasome inhibitors as experimental therapeutics of autoimmune diseases","volume":"17","author":"Verbrugge","year":"2015","journal-title":"Arthritis. Res. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.chembiol.2014.02.006","article-title":"PA28alphabeta reduces size and increases hydrophilicity of 20S immunoproteasome peptide products","volume":"21","author":"Raule","year":"2014","journal-title":"Chem. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Tubio-Santamaria, N., Ebstein, F., Heidel, F.H., and Kruger, E. (2021). Immunoproteasome Function in Normal and Malignant Hematopoiesis. Cells, 10.","DOI":"10.3390\/cells10071577"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/j.seminhematol.2012.04.003","article-title":"The immunoproteasome as a target in hematologic malignancies","volume":"49","author":"Kuhn","year":"2012","journal-title":"Semin. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1002\/anie.201509092","article-title":"A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities","volume":"55","author":"Xin","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1021\/jm500716s","article-title":"Structure-based design of beta1i or beta5i specific inhibitors of human immunoproteasomes","volume":"57","author":"Huber","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13059-016-1012-2","article-title":"Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR","volume":"17","author":"Haeussler","year":"2016","journal-title":"Genome Biol."},{"key":"ref_36","first-page":"e52118","article-title":"Generation of genomic deletions in mammalian cell lines via CRISPR\/Cas9","volume":"95","author":"Bauer","year":"2015","journal-title":"J. Vis. Exp."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nprot.2012.026","article-title":"RGB marking with lentiviral vectors for multicolor clonal cell tracking","volume":"7","author":"Weber","year":"2012","journal-title":"Nat. Protoc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: An open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.3389\/fimmu.2018.02386","article-title":"Immunoproteasome Inhibition Impairs T and B Cell Activation by Restraining ERK Signaling and Proteostasis","volume":"9","author":"Schmidt","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1074-5521(01)00056-4","article-title":"Proteasome inhibitors: From research tools to drug candidates","volume":"8","author":"Kisselev","year":"2001","journal-title":"Chem. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.chembiol.2012.01.003","article-title":"Proteasome inhibitors: An expanding army attacking a unique target","volume":"19","author":"Kisselev","year":"2012","journal-title":"Chem. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1042\/BJ20100383","article-title":"Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit","volume":"430","author":"Blackburn","year":"2010","journal-title":"Biochem. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"40125","DOI":"10.1074\/jbc.M110.160606","article-title":"Nature of pharmacophore influences active site specificity of proteasome inhibitors","volume":"285","author":"Screen","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cell.2011.12.030","article-title":"Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity","volume":"148","author":"Huber","year":"2012","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7177","DOI":"10.1021\/acs.jmedchem.6b00705","article-title":"Structure-Based Design of beta5c Selective Inhibitors of Human Constitutive Proteasomes","volume":"59","author":"Xin","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/bloodadvances.2018016360","article-title":"An inhibitor of proteasome beta2 sites sensitizes myeloma cells to immunoproteasome inhibitors","volume":"2","author":"Daily","year":"2018","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/jm3016987","article-title":"Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites","volume":"56","author":"Geurink","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.3324\/haematol.2013.092411","article-title":"Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors","volume":"98","author":"Niewerth","year":"2013","journal-title":"Haematologica"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"10883","DOI":"10.1038\/s41598-021-90451-9","article-title":"Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein","volume":"11","author":"Jenkins","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Besse, L., Besse, A., Kraus, M., Maurits, E., Overkleeft, H.S., Bornhauser, B., Bourquin, J.P., and Driessen, C. (2021). High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors. Cells, 10.","DOI":"10.3390\/cells10112853"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9241","DOI":"10.1073\/pnas.0501711102","article-title":"IFN-gamma-induced immune adaptation of the proteasome system is an accelerated and transient response","volume":"102","author":"Heink","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8970","DOI":"10.1073\/pnas.94.17.8970","article-title":"The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome","volume":"94","author":"Groettrup","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fimmu.2019.00141","article-title":"Pro-inflammatory Cytokines Alter the Immunopeptidome Landscape by Modulation of HLA-B Expression","volume":"10","author":"Javitt","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1042\/BJ20100878","article-title":"The immunoproteasome, the 20S proteasome and the PA28alphabeta proteasome regulator are oxidative-stress-adaptive proteolytic complexes","volume":"432","author":"Pickering","year":"2010","journal-title":"Biochem. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/bjc.2015.361","article-title":"Serum lactate dehydrogenase and survival following cancer diagnosis","volume":"113","author":"Wulaningsih","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdm595","article-title":"Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes","volume":"19","author":"Wimazal","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1038\/sj.leu.2403963","article-title":"Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)","volume":"19","author":"Germing","year":"2005","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1182\/blood.V128.22.5336.5336","article-title":"Prognostic Significance of Serum LDH in B Cell Chronic Lymphoproliferative Disorders: A Single-Institution Study of 829 Cases in China","volume":"128","author":"Liu","year":"2016","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e46512","DOI":"10.15252\/embr.201846512","article-title":"Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity","volume":"19","author":"Basler","year":"2018","journal-title":"EMBO Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4155\/fmc-2019-0299","article-title":"Immunoproteasome-selective inhibitors: The future of autoimmune diseases?","volume":"12","author":"Zhang","year":"2020","journal-title":"Future Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/1535-7163.MCT-21-0005","article-title":"M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (beta5i) Delivering Efficacy in Multiple Myeloma Models","volume":"20","author":"Sanderson","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"115695","DOI":"10.1016\/j.taap.2021.115695","article-title":"Improved nonclinical safety profile of a novel, highly selective inhibitor of the immunoproteasome subunit LMP7 (M3258)","volume":"429","author":"Sloot","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/5\/838\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:29:58Z","timestamp":1760135398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/5\/838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":63,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["cells11050838"],"URL":"https:\/\/doi.org\/10.3390\/cells11050838","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}